导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.00% | 1937/4773 |
| 近一周 | -0.50% | 1098/5465 |
| 近一月 | -4.34% | 3178/5421 |
| 近一季 | -13.91% | 4208/5231 |
| 近半年 | -6.12% | 3155/4920 |
| 近一年 | 4.89% | 1789/4394 |
| 近两年 | 87.00% | 748/2954 |
| 近三年 | 40.74% | 746/2253 |
| 成立以来 | 161.63% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
0.63% 1490/4961 |
21.63% 1164/5312 |
- - |
- - |
| 2025 | 32.83% 1153/4813 |
3.90% 1023/3635 |
2.43% 1571/4076 |
23.57% 1533/4524 |
1.01% 1594/4813 |
| 2024 | 6.49% 1752/3463 |
-6.26% 2034/2808 |
-8.72% 2274/3014 |
18.54% 991/3129 |
4.98% 654/3463 |
| 2023 | -3.80% 651/2656 |
11.17% 346/2280 |
-2.56% 609/2385 |
-8.09% 1662/2515 |
-3.39% 677/2655 |
| 2022 | -23.64% 1154/2207 |
-18.89% 1410/1919 |
4.43% 1014/2016 |
-13.13% 836/2113 |
3.78% 645/2208 |
| 2021 | 17.29% 238/1822 |
-5.02% 903/1255 |
13.60% 282/1330 |
- 475/1466 |
8.72% 141/1822 |
| 2020 | 30.69% 517/1250 |
-1.48% 223/1028 |
22.43% 207/1067 |
5.51% 914/1164 |
2.69% 973/1184 |
| 2019 | 32.54% 445/1092 |
33.37% 139/754 |
-11.83% 775/804 |
3.55% 246/850 |
8.84% 280/918 |
| 2018 | -35.33% 576/834 |
- - |
- - |
- - |
-12.46% 446/691 |
| 2017 | -11.87% 547/714 |
- - |
- - |
- - |
- - |
| 2016 | -21.62% 456/605 |
- - |
- - |
- - |
- - |
| 2015 | 63.33% 7/575 |
- - |
- - |
- - |
- - |
| 2014 | 22.44% 187/237 |
- - |
- - |
- - |
- - |
| 2013 | 41.09% 6/186 |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 嘉实中创400ETF VS. 长安沪深300非周期A(740101) |